Difference between revisions of "Part:BBa K2976006"
| Line 7: | Line 7: | ||
</p> | </p> | ||
| − | + | ||
===Characteristics=== | ===Characteristics=== | ||
<p>Anti-PD-L1 peptide was designed as a fusion protein with lamp2 and HA tag. With the detection of HA tag, the expression of anti-PD-L1 was confirmed as well. | <p>Anti-PD-L1 peptide was designed as a fusion protein with lamp2 and HA tag. With the detection of HA tag, the expression of anti-PD-L1 was confirmed as well. | ||
Revision as of 13:45, 21 October 2019
Anti-PD-L1 peptide
Usage and Biology
Anti-PD-L1 peptide selectively binds to programmed death ligand 1 (PD-L1), an immune checkpoint protein that is overexpressed in many cancer cell lines. Recent study has demonstrated that the Mtb-infected macrophages express more PD-L1 than normal ones. Thus, PD-L1 could be a promising target for intracellular Mtb therapy. In 2019 CPU_CHINA project, anti-PD-L1 peptide is displayed on the surface of the exosome to specifically targeting the Mtb-infected macrophages.
Characteristics
Anti-PD-L1 peptide was designed as a fusion protein with lamp2 and HA tag. With the detection of HA tag, the expression of anti-PD-L1 was confirmed as well.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]